Kozarek R A, Jiranek G C, Traverso L W
Department of Medicine, Virginia Mason Medical Center, Seattle, Washington.
Am J Surg. 1994 Sep;168(3):223-6. doi: 10.1016/s0002-9610(05)80190-4.
Pancreatic ascites, etiologically related to a leaking pseudocyst or ductal disruption, has been treated medically with hyperalimentation, somatostatin analog, and large-volume paracentesis. Surgery is ultimately required in more than 50% of such patients. Mortality figures in patients with pancreatic ascites approximate 15% to 25% with either treatment modality. We describe 4 patients who were found to have ductal disruptions in conjunction with pancreatic ascites who responded to transpapillary pancreatic duct endoprosthesis placement. There has been no recurrence of ascites in these patients at a mean follow-up of 12 months following stent-retrieval. Further evaluation of endoscopic therapy for pancreatic ascites appears warranted.
胰源性腹水病因与假性囊肿渗漏或导管破裂相关,以往采用胃肠外营养、生长抑素类似物及大量腹腔穿刺术进行内科治疗。超过50%的此类患者最终需要手术治疗。无论采用哪种治疗方式,胰源性腹水患者的死亡率约为15%至25%。我们描述了4例伴有胰源性腹水且发现有导管破裂的患者,这些患者对经乳头胰管内支架置入术有反应。在取出支架后平均随访12个月期间,这些患者腹水未复发。对胰源性腹水的内镜治疗进行进一步评估似乎是必要的。